Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: The Australian experience

Journal of Surgical Oncology

Volumn 99, Issue 2, 2009, Pages 109-113

  Chua, Terence C ^a   Yan, Tristan D ^a   Morris, David L ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Mesothelioma; Peritoneal neoplasms; Peritonectomy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; PEMETREXED; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PALLIATIVE THERAPY; PERITONEUM MESOTHELIOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME; INFUSION; INTRALESIONAL DRUG ADMINISTRATION; MESOTHELIOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERITONEUM TUMOR; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, INTRALESIONAL; INFUSIONS, PARENTERAL; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 59649104856     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21177     Document Type: Article

References (25)

1. Bianchi C, Bianchi T: Malignant mesothelioma: Global incidence and relationship with asbestos. Ind Health 2007;45:379-387.
2. Boffetta P: Epidemiology of peritoneal mesothelioma: A review. Ann Oncol 2007;18:985-990.
3. Acherman YIZ, Welch LS, Bromley CM, et al.: Clinical presentation of peritoneal mesothelioma. Tumori 2003;89:269-273.
4. Yan TD, Welch L, Black D, et al.: A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007;18:827-834.
5. Attanoos RL, Gibbs AR: Pathology of malignant mesothelioma. Histopathology 1997;30:403-418.
6. Gonzalez-Moreno S: Peritoneal surface oncology: A progress report. Eur J Surg Oncol 2006;32:593-596.
7. Jacquet P, Sugarbaker PH: Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49-58.
8. Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995;221:29-42.
9. Castagneto B, Botta M, Aitini E, et al.: Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19:370-373.
10. Yan TD, Yoo D, Sugarbaker PH: Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:948-953.
11. Yan TDB EA, Cerruto CA, Haveric N, et al.: Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007;14:41-49.
12. Yan TD, Links M, Fransi S, et al.: Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy-a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 2007;14:2270-2280.
13. Smeenk RM, Verwaal VJ, Zoetmulder FAN: Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 2007;94:1408-1414.
14. Schmidt U, Dahlke MH, Klempnauer J, et al.: Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005;31:53-58.
15. McQuellon RP, Russell GB, Shen P, et al.: Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol 2008;15:125-133.
16. McQuellon RP, Danhauer SC, Russell GB, et al.: Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2007;14:1105-1113.
17. Tuttle TM, Zhang Y, Greeno E, et al.: Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2006;13:1627-1632.
18. Brigand C, Monneuse O, Mohamed F, et al.: Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: Results of a prospective study. Ann Surg Oncol 2006;13:405-412.
19. Deraco M, De Simone M, Rossi CR, et al.: An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. J Exp Clin Cancer Res 2003;22:41-45.
20. Deraco M, Casali P, Inglese MG, et al.: Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003;83:147-153.
21. Loggie BW, Fleming RA, McQuellon RP, et al.: Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surgeon 2001;67:999-1003.
22. Sebbag G, Yan H, Shmookler BM, et al.: Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000;87:1587-1593.
23. Eltabbakh GH, Piver MS, Hempling RE, et al.: Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999;70:6-12.
24. Feldman AL, Libutti SK, Pingpank JF, et al.: Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560-4567.
25. Witkamp AJ, de Bree E, Van Goethem AR, et al.: Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001;27:365-374.